Affiris AG: Clinical Trials

2 trials sponsored by Affiris AG, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 terminated. 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 22Completed 1, Terminated 1

Follow Affiris AG: new trials by email

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Follow-up Study to Assess Safety and Clinical Activity of Continued AFFITOPE® AD02 Vaccinations of Patients Who Participated in AFF006
AFFITOPE® AD02, Placebo - Alzheimer´s Disease
Phase 2TerminatedAffiris AG1942013-06-012015-06-24
Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease
active: AFFITOPE AD02, control: Placebo - Alzheimer's Disease
Phase 2CompletedAffiris AG3352010-09-012013-12-11

Conditions studied

Alzheimer Disease (2)  ·  Brain Diseases (1)  ·  Dementia (1)  ·  Mental Disorders (1)  ·  Nervous System Diseases (1)  ·  Neurodegenerative Diseases (1)  ·  Tauopathies (1)

Countries

Austria (2)  ·  Croatia (2)  ·  Czechia (2)  ·  France (2)  ·  Germany (2)  ·  Slovakia (2)

Top investigators

Bruno Dubois, Prof (1)  ·  Bruno Dubois, Prof. (1)

Results publications

PMID 40953123

NIH funding

2009 (1)